B cell depletion therapy normalizes circulating follicular TH cells in primary Sjögren syndrome

Journal of Rheumatology

Volumn 44, Issue 1, 2017, Pages 49-58

  Verstappen, Gwenny M ^a   Kroese, Frans G M ^a   Meiners, Petra M ^a   Corneth, Odilia B ^b   Huitema, Minke G ^a   Haacke, Erlin A ^a   Van Der Vegt, Bert ^a   Arends, Suzanne ^a   Vissink, Arjan ^a   Bootsma, Hendrika ^a   Abdulahad, Wayel H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 4; RITUXIMAB; CYTOKINE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; B CELL DEPLETION THERAPY; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; EUROPEAN LEAGUE AGAINST RHEUMATISM SJOGREN SYNDROME DISEASE ACTIVITY INDEX; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SJOEGREN SYNDROME; TH1 CELL; TH17 CELL; TH2 CELL; B LYMPHOCYTE; HELPER CELL; IMMUNOLOGY; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADULT; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; RITUXIMAB; SJOGREN'S SYNDROME; T-LYMPHOCYTES, HELPER-INDUCER; TREATMENT OUTCOME;

EID: 85008197799     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.160313     Document Type: Article

References (50)

1. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjogren's syndrome. J Autoimmun 2010;34:400-7.
2. Kroese FG, Abdulahad WH, Haacke E, Bos NA, Vissink A, Bootsma H. B-cell hyperactivity in primary Sjogren's syndrome. Expert Rev Clin Immunol 2014;10:483-99.
3. Moriyama M, Tanaka A, Maehara T, Furukawa S, Nakashima H, Nakamura S. T helper subsets in Sjogren's syndrome and IgG4-related dacryoadenitis and sialoadenitis: A critical review. J Autoimmun 2014;51:81-8.
4. Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity 2014;41:529-42.
5. Liu R, Su D, Zhou M, Feng X, Li X, Sun L. Umbilical cord mesenchymal stem cells inhibit the differentiation of circulating T follicular helper cells in patients with primary Sjogren's syndrome through the secretion of indoleamine 2,3-dioxygenase. Rheumatology 2015;54:332-42.
6. Szabo K, Papp G, Barath S, Gyimesi E, Szanto A, Zeher M. Follicular helper T cells may play an important role in the severity of primary Sjogren's syndrome. Clin Immunol 2013;147:95-104.
7. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, et al. Reduction of fatigue in Sjogren syndrome with rituximab: Results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008;67:1541-4.
8. Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8.
9. Carubbi F, Cipriani P, Marrelli A, Benedetto P, Ruscitti P, Berardicurti O, et al. Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: A prospective, multi-center, follow-up study. Arthritis Res Ther 2013;15:R172.
10. Moerman RV, Arends S, Meiners PM, Brouwer E, Spijkervet FK, Kroese FG, et al. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann Rheum Dis 2014;73:472-4.
11. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puechal X, et al. Treatment of primary Sjogren syndrome with rituximab: A randomized trial. Ann Intern Med 2014;160:233-42.
12. St Clair EW, Levesque MC, Prak ET, Vivino FB, Alappatt CJ, Spychala ME, et al. Rituximab therapy for primary Sjogren's syndrome: An open-label clinical trial and mechanistic analysis. Arthritis Rheum 2013;65:1097-106.
13. Meiners PM, Arends S, Meijer JM, Moerman RV, Spijkervet FK, Vissink A, et al. Efficacy of retreatment with rituximab in patients with primary Sjogren's syndrome. Clin Exp Rheumatol 2015;33:443-4.
14. Hamza N, Bootsma H, Yuvaraj S, Spijkervet FK, Haacke EA, Pollard RP, et al. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjogren's syndrome after B cell depletion therapy. Ann Rheum Dis 2012;71:1881-7.
15. Lund FE, Randall TD. Effector and regulatory B cells: Modulators of CD4(+) T cell immunity. Nat Rev 2010;10:236-47.
16. Abdulahad WH, Kroese FG, Vissink A, Bootsma H. Immune regulation and B-cell depletion therapy in patients with primary Sjogren's syndrome. J Autoimmun 2012;39:103-11.
17. Shen P, Fillatreau S. Antibody-independent functions of B cells: A focus on cytokines. Nat Rev 2015;15:441-51.
18. Corneth OB, de Bruijn MJ, Rip J, Asmawidjaja PS, Kil LP, Hendriks RW. Enhanced expression of Bruton's tyrosine kinase in B cells drives systemic autoimmunity by disrupting T cell homeostasis. J Immunol 2016;197:58-67.
19. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
20. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al. EULAR Sjogren's syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010;69:1103-9.
21. Seror R, Meiners P, Baron G, Bootsma H, Bowman SJ, Vitali C, et al. Development of the ClinESSDAI: A clinical score without biological domain. A tool for biological studies. Ann Rheum Dis 2016;75:1945-50.
22. Zhu J, Paul WE. CD4 T cells: Fates, functions, and faults. Blood 2008;112:1557-69.
23. Schmitt N, Bentebibel SE, Ueno H. Phenotype and functions of memory Tfh cells in human blood. Trends Immunol 2014; 35:436-42.
24. Stam J, Abdulahad W, Huitema MG, Roozendaal C, Limburg PC, van Stuijvenberg M, et al. Fluorescent cell barcoding as a tool to assess the age-related development of intracellular cytokine production in small amounts of blood from infants. 2011;6:e25690.
25. Abdulahad WH, Meijer JM, Kroese FG, Meiners PM, Vissink A, Spijkervet FK, et al. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjogren's syndrome: A double-blind, placebo-controlled study. Arthritis Rheum 2011;63:1116-23.
26. Simpson N, Gatenby PA, Wilson A, Malik S, Fulcher DA, Tangye SG, et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum 2010;62:234-44.
27. He J, Tsai LM, Leong YA, Hu X, Ma CS, Chevalier N, et al. Circulating precursor CCR7(lo)PD-1(hi) CXCR5(+) CD4(+) T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity 2013;39:770-81.
28. Brkic Z, Versnel MA. Type I IFN signature in primary Sjogren's syndrome patients. Expert Rev Clin Immunol 2014;10:457-67.
29. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015;16:448-57.
30. Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008;454:350-2.
31. Bikker A, Moret FM, Kruize AA, Bijlsma JW, Lafeber FP, van Roon JA. IL-7 drives Th1 and Th17 cytokine production in patients with primary SS despite an increase in CD4 T cells lacking the IL-7Rα. Rheumatology 2012;51:996-1005.
32. Alunno A, Bistoni O, Bartoloni E, Caterbi S, Bigerna B, Tabarrini A, et al. IL-17-producing CD4-CD8- T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjogren's syndrome. Ann Rheum Dis 2013;72:286-92.
33. McGuire HM, Vogelzang A, Ma CS, Hughes WE, Silveira PA, Tangye SG, et al. A subset of interleukin-21+ chemokine receptor CCR9+ T helper cells target accessory organs of the digestive system in autoimmunity. Immunity 2011;34:602-15.
34. Wan Q, Kozhaya L, ElHed A, Ramesh R, Carlson TJ, Djuretic IM, et al. Cytokine signals through PI-3 kinase pathway modulate Th17 cytokine production by CCR6+ human memory T cells. J Exp Med 2011;208:1875-87.
35. Ciccia F, Guggino G, Rizzo A, Alessandro R, Carubbi F, Giardina A, et al. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjogren's syndrome. Rheumatology 2014;53:1313-20.
36. Kang KY, Kim HY, Kwok SK, Ju JH, Park KS, Sun DI, et al. Impact of interleukin-21 in the pathogenesis of primary Sjogren's syndrome: Increased serum levels of interleukin-21 and its expression in the labial salivary glands. Arthritis Res Ther 2011;13:R179.
37. Nguyen CQ, Hu MH, Li Y, Stewart C, Peck AB. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren's syndrome: Findings in humans and mice. Arthritis Rheum 2008;58:734-43.
38. Katsifis GE, Rekka S, Moutsopoulos NM, Pillemer S, Wahl SM. Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome immunopathogenesis. Am J Pathol 2009;175:1167-77.
39. Pollard RP, Abdulahad WH, Bootsma H, Meiners PM, Spijkervet FK, Huitema MG, et al. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome. Ann Rheum Dis 2013;72:2048-50.
40. Reksten TR, Jonsson MV, Szyszko EA, Brun JG, Jonsson R, Brokstad KA. Cytokine and autoantibody profiling related to histopathological features in primary Sjogren's syndrome. Rheumatology 2009;48:1102-6.
41. Gong YZ, Nititham J, Taylor K, Miceli-Richard C, Sordet C, Wachsmann D, et al. Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjogren's syndrome. J Autoimmun 2014;51:57-66.
42. Zhao Y, Lutalo PM, Thomas JE, Sangle S, Choong LM, Tyler JR, et al. Circulating T follicular helper cell and regulatory T cell frequencies are influenced by B cell depletion in patients with granulomatosis with polyangiitis. Rheumatology 2014;53:621-30.
43. Xu X, Shi Y, Cai Y, Zhang Q, Yang F, Chen H, et al. Inhibition of increased circulating Tfh cell by anti-CD20 monoclonal antibody in patients with type 1 diabetes. PLoS One 2013;8:e79858.
44. Delli K, Haacke EA, Kroese FG, Pollard RP, Ihrler S, van der Vegt B, et al. Towards personalised treatment in primary Sjogren's syndrome: Baseline parotid histopathology predicts responsiveness to rituximab treatment. Ann Rheum Dis 2016;75:1933-8.
45. Lindop R, Arentz G, Bastian I, Whyte AF, Thurgood LA, Chataway TK, et al. Long-term Ro60 humoral autoimmunity in primary Sjogren's syndrome is maintained by rapid clonal turnover. Clin Immunol 2013;148:27-34.
46. Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008;58:2993-9.
47. Alunno A, Carubbi F, Bistoni O, Caterbi S, Bartoloni E, Di Benedetto P, et al. IL-17 producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjogren's syndrome: A pilot study. Clin Exp Immunol 2016;184:284-92.
48. Chavele KM, Merry E, Ehrenstein MR. Cutting edge: Circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production. J Immunol 2015;194:2482-5.
49. Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012;209:1001-10.
50. van de Veerdonk FL, Lauwerys B, Marijnissen RJ, Timmermans K, Di Padova F, Koenders MI, et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 2011;63:1507-16.